البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
PREDNISOLONE AS SODIUM PHOSPHATE
KAMADA LTD, ISRAEL
H02AB06
SOLUTION
PREDNISOLONE AS SODIUM PHOSPHATE 1 MG/ML
ORAL
Required
GENETIC S.P.A., ITALY
PREDNISOLONE
Sintredius oral solution is indicated for the treatment of:- Rheumatological disorders and connective tissue diseases such as: • rheumatoid arthritis (for primary chronic disease and maintenance therapy), • systemic lupus erythematosus (non-organ threatening disease), • mild-moderate juvenile dermatomyositis.- Severe or debilitating allergic conditions, not treatable in a conventional manner such as: • bronchial asthma in children, • bronchial asthma in adults (for maintenance therapy).- Sarcoidosis in children and for maintenance therapy in adults.- Acquired haemolytic anaemia (autoimmune, for maintenance therapy).
2021-12-09
PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS )PREPARATIONS( - 1986 The medicine is dispensed with a doctor’s prescription only SINTREDIUS Oral solution ACTIVE SUBSTANCE AND QUANTITY IN UNIT DOSE: prednisolone )as sodium phosphate( 1mg/ml INACTIVE INGREDIENTS AND ALLERGENS IN THE PRODUCT: see section 2 “Important information about some of the ingredients of the medicine” and section 6 “additional information” READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE MEDICINE. This leaflet contains concise information about the medicine. If you have further questions, please refer to the doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar. 1. WHAT IS THE MEDICINE INTENDED FOR? Sintredius is indicated for the treatment of: • Rheumatological disorders and connective tissue diseases such as: rheumatoid arthritis )for primary chronic disease and maintenance therapy(, systemic lupus erythematosus )non-organ threatening disease(, mild-moderate juvenile dermatomyositis. • Severe or debilitating allergic conditions, not treatable in a conventional manner such as: bronchial asthma in children, bronchial asthma in adults )for maintenance therapy(. • Sarcoidosis in children and for maintenance therapy in adults. • Acquired haemolytic anaemia )autoimmune, for maintenance therapy(. Therapeutic group: glucocorticosteroids Sintredius contains the active ingredient prednisolone, which belongs to a group of medicines called corticosteroids or “steroids”. Steroids work by reducing inflammation and lowering the body’s immune response. SINTREDIUS – BENEFIT INFORMATION Corticosteroids occur naturally in the body and help to maintain health and well-being. Boosting your body with extra corticosteroids )such as prednisolone( is an effective way to treat various illnesses involving inflammation in the body. Prednisolone reduces this inflammation, which could otherwise go اقرأ الوثيقة كاملة
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sintredius 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The active ingredient of Sintredius is prednisolone as the sodium phosphate ester. Each 1 ml oral solution contains 1 mg prednisolone (as sodium phosphate). Each 5 ml single-dose container contains 5 mg of prednisolone (as sodium phosphate). Each 5 ml single-dose container contains 0.5 mmole sodium per dose. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Oral Solution. The solution is a clear, light brown solution free from particulate matters. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Sintredius oral solution is indicated for the treatment of: Rheumatological disorders and connective tissue diseases such as: • rheumatoid arthritis (for primary chronic disease and maintenance therapy) • systemic lupus erythematosus (non-organ threatening disease) • mild-moderate juvenile dermatomyositis Severe or debilitating allergic conditions, not treatable in a conventional manner such as: • bronchial asthma in children • bronchial asthma in adults (for maintenance therapy) Sarcoidosis in children and for maintenance therapy in adults Acquired haemolytic anaemia (autoimmune, for maintenance therapy) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The lowest dosage that will produce an acceptable result should be used (See section 4.4); when it is possible to reduce the dosage, this must be accomplished by stages. During prolonged therapy any intercurrent illness, trauma or surgical procedure will require a temporary increase in dosage; if corticosteroids have been stopped following prolonged therapy they may need to be temporarily re-introduced. The medicinal product should preferably be taken as a single dose in the morning. However, divided daily dosages may be employed if required. _NOTE TO THE PRESCRIBER: _ This 5 ml single-dose unit presentation should not be prescribed for doses exceeding 30 mg daily, because opening more than 6 containers in a day may incr اقرأ الوثيقة كاملة